High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients.

BACKGROUND Recent studies demonstrate that lipoprotein-associated phospholipase A2 (Lp-PLA2) is a risk factor for cardiovascular disease presumably deriving from generation of proinflammatory and proatherogenic species through its hydrolytic activity on lipoprotein-associated phospholipids. The goal of this study was to assess the relationship of Lp-PLA2 with a set of thrombogenic, lipid, inflammatory, and metabolic blood markers and to determine whether plasma Lp-PLA2 is a risk factor for recurrent coronary events in postinfarction patients. METHODS Factor analysis on the set of blood markers and Lp-PLA2 was performed for 766 patients of the Thrombogenic Factors and Recurrent Coronary Events (THROMBO) postinfarction study. Recurrent coronary event risk was assessed as a function of blood marker concentrations and Lp-PLA2 by Cox proportional hazards multivariable regression adjusted for significant clinical covariates. RESULTS Factor analysis revealed that Lp-PLA2 was associated with one factor dominated by cholesterol and apolipoprotein B and another factor dominated by HDL-cholesterol and triglycerides, with little association with an inflammatory factor dominated by C-reactive protein. Multivariable analysis demonstrated as significant and independent predictors of risk of secondary coronary events only apolipoprotein B in a model without Lp-PLA2 (hazard ratio, 1.66; 95% confidence interval, 1.14-2.40) and only Lp-PLA2 in a model with Lp-PLA2 included [1.90 (1.31-2.75)]. CONCLUSIONS Lp-PLA2 is a significant and independent predictor of risk for recurrent coronary events in postinfarction patients, and Lp-PLA2 is related to both hypercholesterolemia and high triglyceride-low HDL dyslipidemia in this study population.

[1]  A. Moss,et al.  Thrombogenic factors and recurrent coronary events. , 1999, Circulation.

[2]  P. Kovanen,et al.  Phospholipase A(2) in vascular disease. , 2001, Circulation research.

[3]  A. Hofman,et al.  Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study , 2005, Circulation.

[4]  D. Seligson,et al.  Clinical Chemistry , 1965, Bulletin de la Societe de chimie biologique.

[5]  C. Macphee.  Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. , 2001, Current opinion in pharmacology.

[6]  A. Moss,et al.  Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. , 2004, Atherosclerosis.

[7]  A. Moss,et al.  Serum glucose and triglyceride determine high-risk subgroups in non-diabetic postinfarction patients. , 2005, Atherosclerosis.

[8]  A. Zalewski,et al.  Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[9]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[10]  M. H.,et al.  LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 AS AN INDEPENDENT PREDICTOR OF CORONARY HEART DISEASE , 2000 .

[11]  D. Rainwater,et al.  Electrophoretic separation of LDL and HDL subclasses. , 1998, Methods in molecular biology.

[12]  P. Kovanen,et al.  Phospholipase A(2) in vascular disease. , 2001, Circulation research.

[13]  C. Meisinger,et al.  Lipoprotein-Associated Phospholipase A 2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population , 2004 .

[14]  C. Meisinger,et al.  Lipoprotein-Associated Phospholipase A2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population: Results From the 14-Year Follow-Up of a Large Cohort From Southern Germany , 2004, Circulation.

[15]  Heejung Bang,et al.  Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study , 2004, Circulation.

[16]  E. Brilakis,et al.  Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. , 2005, European heart journal.

[17]  J. Manson,et al.  A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. , 2001, Journal of the American College of Cardiology.

[18]  R. Lavi,et al.  Role of lipoprotein-associated phospholipase A2 in atherosclerosis , 2008, Current atherosclerosis reports.

[19]  C. Packard,et al.  Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease , 2003, Current opinion in lipidology.

[20]  W. Shelledy,et al.  Characterization of a composite gradient gel for the electrophoretic separation of lipoproteins. , 1997, Journal of lipid research.

[21]  C. Packard,et al.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. , 2000, Atherosclerosis.

[22]  A. Tselepis,et al.  Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. , 2002, Atherosclerosis. Supplements.

[23]  P. Ridker,et al.  Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients. , 2003, Atherosclerosis.

[24]  W. Jaross,et al.  Biological effects of secretory phospholipase A2 group IIA on lipoproteins and in atherogenesis , 2002, European journal of clinical investigation.

[25]  C. Packard,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease , 2000 .

[26]  K. Sudhir.  Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. , 2005, The Journal of clinical endocrinology and metabolism.